RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/18/21
RedHill Biopharma delivers revenue growth, commercial expansion and pipeline progress in FY2020 results as focused efforts pay offProactive Investors • 03/18/21
RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsPRNewsWire • 03/18/21
RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021PRNewsWire • 03/11/21
RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary SharesPRNewsWire • 03/04/21
RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary SharesPRNewsWire • 03/02/21
RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary SharesPRNewsWire • 03/01/21
RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.PRNewsWire • 02/23/21
RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 StudyZacks Investment Research • 02/19/21
RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204PRNewsWire • 02/18/21
RedHill Biopharma says first patient dosed in ground-breaking RHB-107 Phase 2/3 study of coronavirus outpatientsProactive Investors • 02/17/21
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of OpaganibPRNewsWire • 01/29/21
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of OpaganibPRNewsWire • 12/31/20